These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 11937989)
1. [Perspectives for drug treatment in Alzheimer's disease]. Allain H; Tribut O; Reymann JM; Polard E; Lecavorzin P; Bentue-Ferrer D Ann Med Interne (Paris); 2001 Dec; 152(8):527-32. PubMed ID: 11937989 [TBL] [Abstract][Full Text] [Related]
2. Medical treatment of Alzheimer's disease: past, present, and future. Ott BR Med Health R I; 2002 Jul; 85(7):210-2. PubMed ID: 12182092 [No Abstract] [Full Text] [Related]
3. [Current therapy of patients with dementia]. Fuchsberger T; Möller HJ; Hampel H MMW Fortschr Med; 2003 May; 145 Suppl 2():49-52, 54. PubMed ID: 14579485 [TBL] [Abstract][Full Text] [Related]
5. [Current strategies of pathogenetic therapy of Alzheimer's disease]. Gavrilova SI; Zharikov GA Vestn Ross Akad Med Nauk; 2001; (7):13-8. PubMed ID: 11523421 [TBL] [Abstract][Full Text] [Related]
6. Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population. Prasher VP Int J Geriatr Psychiatry; 2004 Jun; 19(6):509-15. PubMed ID: 15211527 [TBL] [Abstract][Full Text] [Related]
7. Cholinesterase inhibitors in the clinical management of Alzheimer's disease: importance of early and persistent treatment. Seltzer B J Int Med Res; 2006; 34(4):339-47. PubMed ID: 16989488 [TBL] [Abstract][Full Text] [Related]
8. Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease. Ritchie CW; Ames D; Clayton T; Lai R Am J Geriatr Psychiatry; 2004; 12(4):358-69. PubMed ID: 15249273 [TBL] [Abstract][Full Text] [Related]
14. Strategies for continued successful treatment of Alzheimer's disease: switching cholinesterase inhibitors. Gauthier S; Emre M; Farlow MR; Bullock R; Grossberg GT; Potkin SG Curr Med Res Opin; 2003; 19(8):707-14. PubMed ID: 14687441 [TBL] [Abstract][Full Text] [Related]
15. A clinical overview of cholinesterase inhibitors in Alzheimer's disease. Farlow M Int Psychogeriatr; 2002; 14 Suppl 1():93-126. PubMed ID: 12636182 [TBL] [Abstract][Full Text] [Related]
16. Effective pharmacological management of Alzheimer's disease. Atri A Am J Manag Care; 2011 Nov; 17 Suppl 13():S346-55. PubMed ID: 22214392 [TBL] [Abstract][Full Text] [Related]
17. Treatment of Alzheimer's disease: an evaluation of the cholinergic approach. Lemière J; Van Gool D; Dom R Acta Neurol Belg; 1999 Jun; 99(2):96-106. PubMed ID: 10427352 [TBL] [Abstract][Full Text] [Related]
18. Switching from donepezil or rivastigmine to galantamine in clinical practice. Edwards K; Therriault O'connor J; Gorman C J Am Geriatr Soc; 2004 Nov; 52(11):1965. PubMed ID: 15507085 [No Abstract] [Full Text] [Related]
19. UK government guidance on Alzheimer's drugs postponed. O'Neill MF Drug Discov Today; 2005 Sep; 10(17):1132. PubMed ID: 16182201 [No Abstract] [Full Text] [Related]
20. Cholinesterase inhibitors in Alzheimer's disease: donepezil or rivastigmine? Sharma JC Int J Clin Pract; 2002; 56(6):414-5. PubMed ID: 12166537 [No Abstract] [Full Text] [Related] [Next] [New Search]